Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives - PubMed (original) (raw)
. 2003 Dec 1;63(23):8443-50.
Affiliations
- PMID: 14679008
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives
Jeffrey Cummings et al. Cancer Res. 2003.
Abstract
Colon cancer exhibits inherent insensitivity to chemotherapy by mechanisms that are poorly characterized. We have shown that human colon cancer cells are efficient in drug conjugation catalyzed by UDP-glucuronosyltransferases (UGTs) and now report on the role of glucuronidation in de novo resistance to two topoisomerase I inhibitors. Identification of the UGT responsible for glucuronidation of SN-38 and the anthraquinone NU/ICRF 505 was achieved by first using a panel of human cDNA-expressed isozymes to measure conjugating activity. HT29 colon cancer cells were then probed by reverse transcriptase-PCR, Western Blot analysis, and liquid chromatography with mass spectrometry for their profile and activity of UGT isozymes and screened for effective inhibitors of glucuronidation. Expression analysis was also conducted in colon cancer biopsies and paired adjacent normal colon specimens. UGT1A9 was identified as the isozyme catalyzing biotransformation of the two compounds in HT29 cells and propofol as an effective competitive inhibitor of this metabolism. Inhibition of glucuronidation resulted in up to a 5-fold enhancement in drug activity. The majority of colon cancer biopsies studies expressed UGT protein at levels greater than in HT29 cells but with marked interpatient variations and proficiently glucuronidated the two anticancer drugs. A range of UGT aglycones were capable of modulating glucuronidation in the biopies with octylgallate being 10-fold more potent (ID(50) 24 microM) than propofol. In a subset of tumors (33%), UGT protein levels and activity exceeded that of paired normal colon. Glucuronidation may represent a mechanism of intrinsic drug resistance in colon cancer open to modulation by a range of food additives and proprietary medicines.
Similar articles
- Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.
Cummings J, Ethell BT, Jardine L, Burchell B. Cummings J, et al. Anticancer Res. 2006 May-Jun;26(3B):2189-96. Anticancer Res. 2006. PMID: 16821585 - Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Cummings J, Boyd G, Ethell BT, Macpherson JS, Burchell B, Smyth JF, Jodrell DI. Cummings J, et al. Biochem Pharmacol. 2002 Feb 15;63(4):607-13. doi: 10.1016/s0006-2952(01)00812-7. Biochem Pharmacol. 2002. PMID: 11992628 - Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Maliepaard M, Friedberg TH, Smyth JF, Jodrell DI. Cummings J, et al. Biochem Pharmacol. 2004 Jan 1;67(1):31-9. doi: 10.1016/j.bcp.2003.07.019. Biochem Pharmacol. 2004. PMID: 14667926 - [Glucuronidation of antitumour therapeutics--detoxification, mechanism of resistance or prodrug formation?].
Mróz A, Mazerska Z. Mróz A, et al. Postepy Hig Med Dosw (Online). 2015 Dec 31;69:1462-77. Postepy Hig Med Dosw (Online). 2015. PMID: 27259218 Review. Polish. - The role of glucuronidation in drug resistance.
Mazerska Z, Mróz A, Pawłowska M, Augustin E. Mazerska Z, et al. Pharmacol Ther. 2016 Mar;159:35-55. doi: 10.1016/j.pharmthera.2016.01.009. Epub 2016 Jan 22. Pharmacol Ther. 2016. PMID: 26808161 Review.
Cited by
- Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells.
Liu Y, Zhang F, Zhang XF, Qi LS, Yang L, Guo H, Zhang N. Liu Y, et al. J Biomed Sci. 2012 May 25;19(1):53. doi: 10.1186/1423-0127-19-53. J Biomed Sci. 2012. PMID: 22631075 Free PMC article. - Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.
Fedejko-Kap B, Bratton SM, Finel M, Radominska-Pandya A, Mazerska Z. Fedejko-Kap B, et al. Drug Metab Dispos. 2012 Sep;40(9):1736-43. doi: 10.1124/dmd.112.045401. Epub 2012 Jun 1. Drug Metab Dispos. 2012. PMID: 22659092 Free PMC article. - Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines.
Dates CR, Fahmi T, Pyrek SJ, Yao-Borengasser A, Borowa-Mazgaj B, Bratton SM, Kadlubar SA, Mackenzie PI, Haun RS, Radominska-Pandya A. Dates CR, et al. Cancer Biol Ther. 2015;16(5):714-23. doi: 10.1080/15384047.2015.1026480. Cancer Biol Ther. 2015. PMID: 25996841 Free PMC article. - Virtual Screening for the Discovery of Microbiome β-Glucuronidase Inhibitors to Alleviate Cancer Drug Toxicity.
Challa AP, Hu X, Zhang YQ, Hymes J, Wallace BD, Karavadhi S, Sun H, Patnaik S, Hall MD, Shen M. Challa AP, et al. J Chem Inf Model. 2022 Apr 11;62(7):1783-1793. doi: 10.1021/acs.jcim.1c01414. Epub 2022 Mar 31. J Chem Inf Model. 2022. PMID: 35357819 Free PMC article. - Heterologous expression of active human uridine diphosphate glucuronosyltransferase 1A3 in Chinese hamster lung cells.
Chen YK, Li X, Chen SQ, Zeng S. Chen YK, et al. World J Gastroenterol. 2005 Jan 7;11(1):118-21. doi: 10.3748/wjg.v11.i1.118. World J Gastroenterol. 2005. PMID: 15609409 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials